See more : SPC Nickel Corp. (SPCNF) Income Statement Analysis – Financial Results
Complete financial analysis of PT Kalbe Farma Tbk. (PTKFY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PT Kalbe Farma Tbk., a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- United States Lime & Minerals, Inc. (USLM) Income Statement Analysis – Financial Results
- Viaplay Group AB (publ) (VPLAY-A.ST) Income Statement Analysis – Financial Results
- Namibia Critical Metals Inc. (NMREF) Income Statement Analysis – Financial Results
- Osisko Development Corp. (ODV) Income Statement Analysis – Financial Results
- Middle East Pharmaceutical Industries Co. (4016.SR) Income Statement Analysis – Financial Results
PT Kalbe Farma Tbk. (PTKFY)
About PT Kalbe Farma Tbk.
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30,449.13B | 28,933.50B | 26,261.19B | 23,112.65B | 22,633.48B | 21,074.31B | 20,182.12B | 19,374.23B | 17,887.46B | 17,368.53B | 16,002.13B | 13,636.41B | 10,911.86B | 10,226.79B | 9,087.35B | 7,877.37B | 7,004.91B | 6,071.55B | 5,870.94B |
| Cost of Revenue | 18,625.89B | 17,229.44B | 14,977.41B | 12,866.33B | 12,390.01B | 11,226.38B | 10,369.84B | 9,886.26B | 9,295.89B | 8,892.74B | 8,323.02B | 7,102.97B | 5,360.69B | 5,060.40B | 4,575.41B | 4,073.73B | 3,453.28B | 2,972.91B | 2,907.62B |
| Gross Profit | 11,823.25B | 11,704.07B | 11,283.78B | 10,246.32B | 10,243.47B | 9,847.93B | 9,812.28B | 9,487.97B | 8,591.58B | 8,475.80B | 7,679.11B | 6,533.43B | 5,551.17B | 5,166.39B | 4,511.94B | 3,803.64B | 3,551.63B | 3,098.64B | 2,963.31B |
| Gross Profit Ratio | 38.83% | 40.45% | 42.97% | 44.33% | 45.26% | 46.73% | 48.62% | 48.97% | 48.03% | 48.80% | 47.99% | 47.91% | 50.87% | 50.52% | 49.65% | 48.29% | 50.70% | 51.04% | 50.47% |
| Research & Development | 329.62B | 288.34B | 532.79B | 483.76B | 543.46B | 352.03B | 494.17B | 461.80B | 483.21B | 473.18B | 467.16B | 443.60B | 0.00 | 94.93B | 78.76B | 54.27B | 45.93B | 27.87B | 40.95B |
| General & Administrative | 562.77B | 501.54B | 516.14B | 432.28B | 401.88B | 354.92B | 363.22B | 427.13B | 470.16B | 450.98B | 319.49B | 247.94B | 677.74B | 209.94B | 518.79B | 453.36B | 397.31B | 368.71B | 314.07B |
| Selling & Marketing | 3,595.53B | 3,549.16B | 3,344.77B | 2,915.57B | 3,198.40B | 3,104.38B | 3,142.47B | 3,101.63B | 2,653.61B | 2,631.71B | 2,433.28B | 2,051.82B | 2,905.47B | 2,699.58B | 2,348.51B | 2,153.30B | 1,979.03B | 1,630.79B | 1,548.27B |
| SG&A | 7,591.03B | 4,050.71B | 3,860.92B | 3,347.85B | 3,600.28B | 3,459.30B | 3,505.69B | 3,528.76B | 3,123.77B | 3,082.69B | 2,752.77B | 2,299.76B | 3,583.20B | 2,909.52B | 2,867.30B | 2,606.66B | 2,376.35B | 1,999.50B | 1,862.35B |
| Other Expenses | 0.00 | 3,133.15B | 2,888.35B | 2,868.79B | 2,795.24B | 35.76B | 30.45B | 39.53B | 40.86B | 32.11B | -19.91B | -5.35B | -57.84B | -54.73B | -11.90B | -9.22B | -7.48B | 11.23B | -6.61B |
| Operating Expenses | 7,920.65B | 7,472.20B | 7,282.06B | 6,700.40B | 6,938.98B | 6,555.27B | 6,576.10B | 6,378.27B | 5,885.72B | 5,650.49B | 5,097.89B | 4,287.30B | 3,583.20B | 3,375.48B | 2,946.07B | 2,660.93B | 2,422.28B | 2,027.37B | 1,903.30B |
| Cost & Expenses | 26,818.30B | 24,701.63B | 22,259.47B | 19,566.73B | 19,328.99B | 17,781.65B | 16,945.94B | 16,264.53B | 15,181.60B | 14,543.23B | 13,420.91B | 11,390.27B | 8,943.89B | 8,435.89B | 7,521.47B | 6,734.65B | 5,875.56B | 5,000.28B | 4,810.92B |
| Interest Income | 88.22B | 81.83B | 110.79B | 151.56B | 137.94B | 125.79B | 134.91B | 132.33B | 101.33B | 63.37B | 50.43B | 74.47B | 96.93B | 54.98B | 65.47B | 54.02B | 66.39B | 78.06B | 89.52B |
| Interest Expense | 82.96B | 41.23B | 45.49B | 75.84B | 31.06B | 19.66B | 26.13B | 18.04B | 9.96B | 38.38B | 14.42B | 4.78B | 13.17B | 20.72B | 53.45B | 52.05B | 56.35B | 70.53B | 92.98B |
| Depreciation & Amortization | 333.65B | 732.10B | 673.81B | 637.12B | 509.79B | 462.89B | 448.55B | 440.76B | 217.38B | 191.58B | 152.45B | 121.98B | 39.09B | 59.83B | -41.35B | 87.36B | 85.67B | 90.17B | 64.48B |
| EBITDA | 4,022.85B | 5,246.05B | 4,874.46B | 4,354.33B | 3,952.83B | 3,799.03B | 3,726.13B | 3,560.10B | 2,948.22B | 2,995.56B | 2,739.40B | 2,438.63B | 2,217.01B | 2,006.04B | 1,577.91B | 1,230.07B | 1,215.02B | 1,162.55B | 1,124.49B |
| EBITDA Ratio | 13.21% | 16.86% | 17.17% | 17.20% | 16.29% | 17.64% | 17.94% | 17.84% | 17.06% | 17.72% | 17.19% | 17.93% | 18.39% | 18.10% | 16.78% | 15.62% | 17.35% | 19.13% | 19.15% |
| Operating Income | 3,630.84B | 4,492.19B | 4,160.66B | 3,637.01B | 3,417.19B | 3,292.65B | 3,236.18B | 3,109.70B | 2,705.86B | 2,825.31B | 2,581.22B | 2,246.14B | 1,967.97B | 1,790.90B | 1,565.87B | 1,142.71B | 1,129.35B | 1,071.27B | 1,060.01B |
| Operating Income Ratio | 11.92% | 15.53% | 15.84% | 15.74% | 15.10% | 15.62% | 16.03% | 16.05% | 15.13% | 16.27% | 16.13% | 16.47% | 18.04% | 17.51% | 17.23% | 14.51% | 16.12% | 17.64% | 18.06% |
| Total Other Income/Expenses | -252.93M | -33.30B | -17.40B | 77.29B | -14.58B | 13.75B | 10.92B | -23.47B | 31.93B | -46.16B | -8.70B | 61.88B | -10.17B | -20.47B | -94.80B | 35.31B | 29.31B | 18.81B | -44.45B |
| Income Before Tax | 3,630.58B | 4,458.90B | 4,143.26B | 3,627.63B | 3,402.62B | 3,306.40B | 3,241.19B | 3,091.19B | 2,720.88B | 2,763.70B | 2,572.52B | 2,308.02B | 1,987.26B | 1,770.43B | 1,471.07B | 1,178.02B | 1,158.67B | 1,090.08B | 1,015.57B |
| Income Before Tax Ratio | 11.92% | 15.41% | 15.78% | 15.70% | 15.03% | 15.69% | 16.06% | 15.96% | 15.21% | 15.91% | 16.08% | 16.93% | 18.21% | 17.31% | 16.19% | 14.95% | 16.54% | 17.95% | 17.30% |
| Income Tax Expense | 852.18B | 1,008.81B | 911.26B | 828.01B | 865.02B | 809.14B | 787.94B | 740.30B | 663.19B | 642.61B | 602.07B | 532.92B | 464.30B | 426.64B | 421.41B | 352.52B | 347.02B | 325.72B | 310.54B |
| Net Income | 2,766.75B | 3,382.21B | 3,183.62B | 2,733.26B | 2,506.76B | 2,457.13B | 2,403.61B | 2,299.73B | 2,004.24B | 2,064.69B | 1,919.51B | 1,733.93B | 1,522.96B | 1,343.80B | 1,049.67B | 825.50B | 811.65B | 764.36B | 705.02B |
| Net Income Ratio | 9.09% | 11.69% | 12.12% | 11.83% | 11.08% | 11.66% | 11.91% | 11.87% | 11.20% | 11.89% | 12.00% | 12.72% | 13.96% | 13.14% | 11.55% | 10.48% | 11.59% | 12.59% | 12.01% |
| EPS | 59.81 | 14.54K | 13.58K | 11.66K | 10.70K | 10.48K | 10.26K | 9.81K | 8.55K | 8.82K | 8.20K | 7.40K | 6.40K | 5.48K | 3.88K | 2.88K | 2.80K | 2.68K | 2.48K |
| EPS Diluted | 59.81 | 14.54K | 13.58K | 11.66K | 10.70K | 10.48K | 10.26K | 9.81K | 8.55K | 8.82K | 8.20K | 7.40K | 6.40K | 5.48K | 3.88K | 2.88K | 2.80K | 2.68K | 2.48K |
| Weighted Avg Shares Out | 46.26B | 232.58M | 234.36M | 234.37M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.36M | 239.43M | 243.88M | 252.25M | 253.90M | 253.90M |
| Weighted Avg Shares Out (Dil) | 46.26B | 232.58M | 234.36M | 234.37M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.38M | 234.36M | 239.43M | 243.88M | 252.25M | 253.90M | 253.90M |
Source: https://incomestatements.info
Category: Stock Reports